Mihály Balogh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8758534/publications.pdf

Version: 2024-02-01

933447 996975 22 265 10 15 citations g-index h-index papers 22 22 22 260 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Glycine transporter inhibitors: A new avenue for managing neuropathic pain. Brain Research Bulletin, 2019, 152, 143-158.	3.0	30
2	The Peripheral Versus Central Antinociception of a Novel Opioid Agonist: Acute Inflammatory Pain in Rats. Neurochemical Research, 2018, 43, 1250-1257.	3.3	28
3	New Morphine Analogs Produce Peripheral Antinociception within a Certain Dose Range of Their Systemic Administration. Journal of Pharmacology and Experimental Therapeutics, 2016, 359, 171-181.	2.5	23
4	A comprehensive time course and correlation analysis of indomethacin-induced inflammation, bile acid alterations and dysbiosis in the rat small intestine. Biochemical Pharmacology, 2021, 190, 114590.	4.4	22
5	A new potent analgesic agent with reduced liability to produce morphine tolerance. Brain Research Bulletin, 2015, 117, 32-38.	3.0	20
6	Efficacy-Based Perspective to Overcome Reduced Opioid Analgesia of Advanced Painful Diabetic Neuropathy in Rats. Frontiers in Pharmacology, 2019, 10, 347.	3.5	17
7	Angiotensin receptors and neuropathic pain. Pain Reports, 2021, 6, e869.	2.7	17
8	On the Role of Peripheral Sensory and Gut Mu Opioid Receptors: Peripheral Analgesia and Tolerance. Molecules, 2020, 25, 2473.	3.8	16
9	Effects of articaine on [3 H]noradrenaline release from cortical and spinal cord slices prepared from normal and streptozotocin-induced diabetic rats and compared to lidocaine. Brain Research Bulletin, 2017, 135, 157-162.	3.0	15
10	Pharmacological Evidence on Augmented Antiallodynia Following Systemic Co-Treatment with GlyT-1 and GlyT-2 Inhibitors in Rat Neuropathic Pain Model. International Journal of Molecular Sciences, 2021, 22, 2479.	4.1	12
11	Comparisons of In Vivo and In Vitro Opioid Effects of Newly Synthesized 14-Methoxycodeine-6-O-sulfate and Codeine-6-O-sulfate. Molecules, 2020, 25, 1370.	3.8	11
12	14-O-Methylmorphine: A Novel Selective Mu-Opioid Receptor Agonist with High Efficacy and Affinity. European Journal of Pharmacology, 2017, 814, 264-273.	3.5	9
13	Shedding Light on the Pharmacological Interactions between ν-Opioid Analgesics and Angiotensin Receptor Modulators: A New Option for Treating Chronic Pain. Molecules, 2021, 26, 6168.	3.8	7
14	Biochemical and pharmacological characterization of three opioid-nociceptin hybrid peptide ligands reveals substantially differing modes of their actions. Peptides, 2018, 99, 205-216.	2.4	6
15	Lack of Small Intestinal Dysbiosis Following Long-Term Selective Inhibition of Cyclooxygenase-2 by Rofecoxib in the Rat. Cells, 2019, 8, 251.	4.1	6
16	Similarity and dissimilarity in antinociceptive effects of dipeptidyl-peptidase 4 inhibitors, Diprotin A and vildagliptin in rat inflammatory pain models following spinal administration. Brain Research Bulletin, 2019, 147, 78-85.	3.0	6
17	Chronic treatment with rofecoxib but not ischemic preconditioning of the myocardium ameliorates early intestinal damage following cardiac ischemia/reperfusion injury in rats. Biochemical Pharmacology, 2020, 178, 114099.	4.4	6
18	New opioid receptor antagonist: Naltrexone-14-O-sulfate synthesis and pharmacology. European Journal of Pharmacology, 2017, 809, 111-121.	3.5	5

MihÃily Balogh

#	Article	lF	CITATIONS
19	Targeting Neuroimmune Interactions in Diabetic Neuropathy with Nanomedicine. Antioxidants and Redox Signaling, 2022, 36, 122-143.	5.4	5
20	Analysing the effect of I1 imidazoline receptor ligands on DSS-induced acute colitis in mice. Inflammopharmacology, 2017, 25, 107-118.	3.9	4
21	Chronic cyclooxygenase-2 inhibition does not cause gastrointestinal damage in the rat. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO2-6-22.	0.0	O
22	Targeted Imaging and Therapeutic Technologies in Neuroregeneration., 2021,, 101-120.		0